UTI with Suspected Urosepsis
68F Β· Inpatient Med-Surg Β· COPD Γ 6 years Β· Updated April 15, 2026
- Assess
- Recognize
- Analyze
- Prioritize
- Solutions
- Plan
- Implement
- Evaluate
Phase Status β Click to Drill In
π Living Care Plan Summary
Updated: Apr 15, 2026π΄ URGENT β IV Antibiotic Order Outstanding
E. coli >100k CFU confirmed on UA. IV Ceftriaxone 1g q24h not yet ordered. Call HCP immediately with UA result.
Active NANDA-I Diagnoses
| # | Diagnosis | Code | Outcome Status | Intervention |
|---|---|---|---|---|
| 1 | Risk for Sepsis | 00275 | β οΈ Partially Met Lactate <2.0, but antibiotic not started | π΄ Overdue |
| 2 | Impaired Urinary Elimination | 00016 | π΄ Not Met Pathogen confirmed, treatment not initiated | π΄ Pending order |
| 3 | Impaired Gas Exchange | 00030 | β
Met SpOβ 92% on 2L NC β COPD target 88β92% | β Oβ in place |
| 4 | Acute Confusion | 00128 | β
Progressing More alert and responsive | β Oβ + reorientation |
| 5 | Acute Pain | 00132 | β Not Met Pain unchanged, analgesic not given | β³ Pending order |
Intervention Tracker
| Intervention | Status | Notes |
|---|---|---|
| Supplemental Oβ (2L NC) | β Done | SpOβ 92% β COPD target achieved |
| Fall precautions | β Done | Bed lowest, rails up, call light in reach |
| Continuous SpOβ monitoring | β Done | Per unit protocol |
| Blood cultures Γ 2 | β Drawn | Results pending |
| CBC / BMP / Lactate | β Drawn | Lactate <2.0 confirmed; others pending |
| UA + reflex culture | β Resulted | +nitrites, +leukocyte esterase, E. coli >100k CFU β culture/sensitivity pending (24β48h) |
| Reorientation q1h | β In progress | Patient more alert β active engagement feasible |
| IV Antibiotics (Ceftriaxone 1g IV) | π΄ Overdue | E. coli confirmed; no order yet β escalate to HCP immediately |
| IV access | β οΈ Unknown | Not documented |
| Analgesic (acetaminophen) | β³ Pending | Include in HCP call |
| Medication reconciliation | β Not complete | Critical gap β meds affect antibiotic safety |
Outstanding Actions
- π΄ Urgent Call HCP with UA result β request IV Ceftriaxone 1g q24h + analgesic order. E. coli >100k confirmed β antibiotic is overdue.
- π΄ Urgent Confirm IV access is established. Required before antibiotic administration.
- β οΈ Needed Medication reconciliation β full med list. Affects antibiotic safety, drug interactions, HR interpretation.
- β οΈ Needed Formal orientation assessment. Patient now alert enough to assess.
- π Pending Serial lactate if symptoms persist or worsen after antibiotic initiation.
- π Pending Patient/family teaching when patient fully alert.
Current Loop Indicators
| Trigger | Re-Enter | Status |
|---|---|---|
| β UA resulted β E. coli >100k CFU | Phase 3 β Analyze Cues | β Complete |
| Culture/sensitivity results (24β48h) | Phase 3 β Analyze Cues (antibiotic de-escalation) | β³ Awaiting |
| CBC / BMP / blood cultures result | Phase 3 β Analyze Cues (organ dysfunction) | β³ Awaiting |
| Antibiotic initiated | Phase 7 + Phase 8 (re-evaluate 4β6h post) | β³ Awaiting order |
| AMS resolves or worsens | Phase 4 β Prioritize Hypotheses | β³ Monitoring |
1
Assess
ADPIE: Assessment CJMM: Data Gathering
1.1 Subjective Data
| Category | Finding |
|---|---|
| Chief complaint | Dysuria (no hematuria), urinary frequency, urgency, suprapubic pain |
| Medical history | COPD Γ 6 years |
| Current medications | Unknown β medication reconciliation not yet completed |
| Allergies | Unknown |
| Patient concerns | Unable to fully assess β patient lethargic |
1.2 Objective Data
| Finding | Value | Reference |
|---|---|---|
| Temperature | 98.3Β°F | Normal (afebrile) |
| Heart Rate | 68 bpm | Within normal limits |
| Blood Pressure | 138/82 mmHg | Elevated β Stage 1 HTN |
| Respiratory Rate | 19 breaths/min | Within normal limits |
| SpOβ | 88% on room air | β οΈ Critical in context of COPD |
| Mental status | Lethargic β drowsy but arousable | Change from baseline |
| CVA tenderness | Absent | No costovertebral angle involvement |
| Focal tenderness | Absent | No rebound, guarding |
1.3 Diagnostic Tests
- β Resulted UA + reflex culture β +nitrites, +leukocyte esterase, E. coli >100,000 CFU/mL β culture/sensitivity pending (24β48h)
- β³ Pending Blood cultures Γ 2 β drawn
- β³ Pending CBC β drawn
- β³ Pending BMP β drawn
- β Partial Lactate β confirmed <2.0; serial monitoring ongoing
1.4 Baseline Documentation Summary
Afebrile 68F on med-surg with classic lower UTI triad (dysuria, frequency, urgency, suprapubic pain), presenting atypically with new-onset lethargy and SpOβ 88% on room air. COPD adds respiratory vulnerability. Medications unknown β critical gap for clinical interpretation.
2
Recognize Cues
ADPIE: Assessment+ CJMM: Step 1
2.1 Cue Sorting
| Cue | Relevant | Irrelevant | Rationale |
|---|---|---|---|
| Dysuria, frequency, urgency, suprapubic pain | β | Classic lower UTI triad | |
| No hematuria | β | Absent β does not redirect diagnosis | |
| No CVA tenderness | β | Pyelonephritis less supported without this | |
| SpOβ 88% on RA | β | Critical β below safe threshold for COPD patient | |
| New-onset lethargy (change from baseline) | β | AMS = systemic involvement or sepsis signal | |
| HR 68 (normal) | β | May be masked by beta-blocker β cannot dismiss | |
| Temp 98.3Β°F (afebrile) | β | Classic atypical sepsis in older adults | |
| BP 138/82 | β | Elevated; watch MAP drop = sepsis signal | |
| COPD Γ 6 years | β | Alters SpOβ targets; increases hypoxia risk |
2.2 Abnormal Findings
| Finding | Why Abnormal | Urgency |
|---|---|---|
| SpOβ 88% on RA | Below safe threshold; COPD target is 88β92% on Oβ | π΄ Critical |
| New-onset lethargy | AMS in older adult = systemic deterioration signal | π΄ Critical |
| Afebrile despite infection | Older adults may not mount fever; masks sepsis | β οΈ Deceptive |
| HR 68 with possible infection | May be pharmacologically masked (beta-blocker unknown) | β οΈ Deceptive |
| BP 138/82 | Elevated; watch for downward drift (MAP <65) | π Monitor |
2.3 Urgent / Time-Sensitive Cues
2.4 SBAR β HCP Notification (Phase 2 Checkpoint)
S: I'm calling about Mrs. [Patient], 68F on 4 West with dysuria and urinary symptoms.
B: PMH COPD Γ 6 years. Admitted with urinary frequency, urgency, dysuria, suprapubic pain. No hematuria. Afebrile at 98.3Β°F. Meds unknown.
A: SpOβ 88% on room air β new. Mental status lethargic and drowsy but arousable β change from baseline. HR 68, BP 138/82, RR 19. UA and cultures sent. No Oβ order currently in place.
R: Requesting order for supplemental Oβ, sepsis workup (blood cultures, CBC, BMP, lactate), and antibiotic initiation. Requesting q1h VS order. Will you be coming to assess?
3
Analyze Cues
ADPIE: Diagnosis (input) CJMM: Step 2 UA Updated
3.1 Cue Clusters
| Cluster | Cues | Implication |
|---|---|---|
| Lower UTI | Dysuria, frequency, urgency, suprapubic pain, no CVA tenderness | Bladder-localized infection; possible ascending |
| Urosepsis / Systemic Response | New AMS, afebrile, SpOβ 88%, HR 68 (possibly masked) | Infection may have crossed into systemic response |
| Respiratory Compromise | SpOβ 88% on RA, COPD Γ 6yr, RR 19 | Baseline impaired gas exchange worsened by infection |
| Atypical Sepsis (older adult) | No fever, no tachycardia, AMS change | Blunted inflammatory response; classic masking pattern |
3.2 Pathophysiological Explanation
- UTI β Urosepsis pathway: E. coli (confirmed gram-negative rod) enters bloodstream via urinary tract β endotoxin release β SIRS β sepsis β organ dysfunction if untreated. Gram-negative bacteremia is the most common pathogen in urosepsis.
- Blunted fever response: Older adults have impaired thermoregulation; afebrile presentation does NOT rule out serious infection β confirmed here with active E. coli bacteriuria.
- Medication masking: Unknown medications β if patient takes beta-blockers, HR 68 may mask expected tachycardia of sepsis.
- Hypoxia + COPD + Infection: V/Q mismatch worsened by systemic inflammation; SpOβ 88% on RA was clinically significant β now improved to 92% on 2L NC.
- AMS + Hypoxia correlation: AMS improving with Oβ correction β lethargy was likely primarily hypoxia-driven, though sepsis-mediated delirium cannot be fully excluded until culture results return.
- Antibiotic pharmacology β E. coli specific: Nitrofurantoin EXCLUDED (inadequate serum levels for systemic infection); fluoroquinolone and TMP-SMX resistance must be confirmed via sensitivity before use; IV ceftriaxone is appropriate empirical choice.
3.3 Cross-System Relationships
Lower UTI (bladder)
β Ascending infection risk (kidneys)
β Bacteremia risk (bloodstream)
β SIRS/Sepsis β AMS + hemodynamic instability
β Compounded by COPD β SpOβ 88% worsens under systemic stress
β Medications unknown β masking HR response 3.4 Links to Clinical Conditions
| Condition | Supporting Cues | Against |
|---|---|---|
| Urosepsis | E. coli >100k confirmed AMS (improving), afebrile with infection, age, SpOβ 88% | Lactate <2.0, HR 68, no hypotension; AMS improving |
| Delirium (hypoxia-driven) | AMS change from baseline; improving with Oβ | Less likely sepsis-mediated given AMS response to Oβ |
| Pyelonephritis | E. coli UTI with urosepsis risk, AMS | No CVA tenderness; not yet proven ascending |
| COPD Exacerbation | SpOβ 88% on admission, COPD history | SpOβ improved to 92% on 2L NC; no wheezing documented |
| Uncomplicated Cystitis | GU triad, E. coli confirmed | Does NOT explain AMS or SpOβ drop β excluded as sole diagnosis |
4
Prioritize Hypotheses
ADPIE: Diagnosis (output) CJMM: Step 3
4.1 Differential Diagnoses
| Rank | Hypothesis | Urgency | Likelihood | Risk if Missed |
|---|---|---|---|---|
| 1 | Urosepsis / Early Sepsis | π΄ Critical | High | Death, organ failure |
| 2 | Delirium (hypoxia-driven or sepsis-mediated) | π΄ Urgent | High | Falls, aspiration, harm |
| 3 | Impaired Gas Exchange (COPD + infection) | π΄ Urgent | High | Respiratory failure |
| 4 | Pyelonephritis | β οΈ Serious | Moderate | Ascending sepsis if untreated |
| 5 | Uncomplicated UTI | π Moderate | Low (alone) | Inadequate β does not explain full picture |
| 6 | Hypertensive episode | π Monitor | Low | Does not explain AMS or SpOβ |
4.2 Priority Nursing Diagnoses (NANDA-I)
| # | NANDA-I Diagnosis | Code | Defining Characteristics | Related Factors |
|---|---|---|---|---|
| 1 | Risk for Sepsis | 00275 | AMS (improving), afebrile with confirmed E. coli bacteriuria, SpOβ 88% on admission | Confirmed E. coli UTI, age, COPD, immunosenescence β antibiotic not yet started |
| 2 | Impaired Urinary Elimination | 00016 | Frequency, urgency, dysuria; UA confirms E. coli >100k CFU | Confirmed bacterial UTI β E. coli; antibiotic initiation outstanding |
| 3 | Impaired Gas Exchange | 00030 | SpOβ 88% on RA (improved to 92% on 2L NC) | COPD Γ 6yr, systemic infection, V/Q mismatch |
| 4 | Acute Confusion | 00128 | Lethargy improving; was drowsy but arousable | Hypoxia (primary driver β AMS responding to Oβ), infection, age |
| 5 | Acute Pain | 00132 | Dysuria, suprapubic pain, urinary urgency β unchanged | UTI bladder inflammation; analgesic not yet administered |
4.3 Ruled-Out Hypotheses
- Uncomplicated cystitis alone: Cannot explain SpOβ 88% or new AMS β rejected as sole diagnosis.
- Hypertensive crisis: BP 138/82 is elevated but not crisis level; does not drive clinical picture.
5
Generate Solutions
ADPIE: Planning (outcomes) CJMM: Step 4a
5.1 SMART Outcome Statements
| Diagnosis | SMART Outcome | Timeframe |
|---|---|---|
| Risk for Sepsis | Lactate <2.0 (confirmed); no hemodynamic deterioration; antibiotics initiated within 1h of UA result | Immediate |
| Impaired Urinary Elimination | β Pathogen confirmed (E. coli >100k CFU); antibiotic initiated within 1h of result; decreased dysuria within 24h | NOW |
| Impaired Gas Exchange | SpOβ β₯88% on β€4L NC (COPD target); β 92% on 2L NC achieved | β Met β maintain |
| Acute Confusion | Patient oriented to name/place/time; arouses to voice | 4 hours |
| Acute Pain | Patient rates pain β€3/10 after analgesic | 1h post-analgesic |
5.2 Intervention Options
| Diagnosis | Options |
|---|---|
| Risk for Sepsis | π΄ Escalate to HCP now with UA results β antibiotic order outstanding; q1h VS ongoing; sepsis protocol if lactate β₯2.0; IV access; fluid challenge if MAP <65 |
| Impaired Urinary Elimination | π΄ Antibiotic IMMEDIATELY β E. coli confirmed; IV Ceftriaxone 1g q24h preferred; await sensitivity before stepping to oral; encourage oral fluids if tolerated |
| Impaired Gas Exchange | β Oβ 2L NC in place; SpOβ 92% (COPD target met); maintain; reassess with serial monitoring |
| Acute Pain | Non-opioid analgesic (acetaminophen); phenazopyridine if ordered (check BMP for renal function first); reassess 1h post |
| Acute Confusion | β Oβ in place (primary intervention); reorientation q1h; patient now more alert β engage actively; low-stimulation environment |
Antibiotic Exclusion Table
| Antibiotic | Status | Reason |
|---|---|---|
| Nitrofurantoin | β Excluded | Inadequate serum/blood levels β not appropriate when systemic infection (urosepsis) is possible |
| TMP-SMX | β οΈ Hold | E. coli resistance 15β25% regionally; await sensitivity |
| Fluoroquinolone | β οΈ Hold | Resistance increasing; await sensitivity; avoid if SSRI/QTc concerns (meds unknown) |
| IV Ceftriaxone | β First-line | Gram-negative coverage; adequate serum levels; safe pending allergy confirmation |
| Carbapenem | Reserve | For ESBL or resistant E. coli β await sensitivity |
5.3 Benefits and Potential Harms
| Intervention | Benefit | Risk |
|---|---|---|
| Supplemental Oβ | Corrects hypoxia, may resolve AMS | Over-oxygenation β hypercapnia in COPD; target 88β92% only |
| Antibiotics | Treats infection, prevents sepsis progression | Allergy unknown; drug-drug interactions unknown; culture before start |
| IV Fluids | Supports hemodynamics if sepsis | Fluid overload risk in COPD; use conservative strategy |
| Phenazopyridine | Urinary analgesic | Contraindicated if renal impairment (BMP pending); stains urine orange |
5.4 Evidence Base
- π Sepsis-3 / SSC 2021: lactate β₯2.0, blood cultures before antibiotics, 1-hour bundle; gram-negative bacteremia = high urosepsis risk
- π IDSA UTI Guidelines 2022: IV ceftriaxone preferred empiric for complicated UTI or urosepsis risk; nitrofurantoin NOT for systemic infection
- π BTS / GOLD: SpOβ target 88β92% for COPD on supplemental Oβ β achieved
- π NICE Delirium: treat root cause first; minimize antipsychotics; reorientation
- π ASHP/IDSA Antibiogram Guidance: local E. coli resistance patterns guide TMP-SMX and fluoroquinolone use
6
Plan
ADPIE: Planning (docs) CJMM: Step 4b
6.1 Sequenced Interventions
| # | Intervention | Priority | By | When |
|---|---|---|---|---|
| 1 | Apply Oβ 2L NC; target SpOβ 88β92% | π΄ | RN | Now |
| 2 | Continuous SpOβ monitoring; reassess q15 min | π΄ | RN | Ongoing |
| 3 | Establish IV access (18g or larger) | π΄ | RN | Now |
| 4 | Obtain blood cultures Γ 2 (before antibiotics) | π΄ | RN | Before abx |
| 5 | Draw CBC, BMP, lactate | π΄ | RN | Now |
| 6 | Implement fall precautions; bed lowest; call light in reach | π΄ | RN + UAP | Now |
| 7 | Reorientation: name, place, time, nurse name; calm tone | β οΈ | RN + UAP | q1h |
| 8 | q1h vital signs including SpOβ and neuro check | β οΈ | RN + UAP | Ongoing |
| 9 | Initiate antibiotics when ordered | β οΈ | RN | Per HCP order |
| 10 | Administer analgesic per order | β οΈ | RN | Per order |
| 11 | Conservative IV fluids if MAP <65 or lactate β₯2.0 | β οΈ | RN | Per HCP |
| 12 | Medication reconciliation β obtain full med list | π | RN | This shift |
6.2 Delegation
| Task | RN | UAP |
|---|---|---|
| Oβ application | β Initiates | Monitors and reports |
| Fall precautions | β Orders | β Implements |
| Vital signs | β Interprets | β Obtains and documents |
| Reorientation | β Assesses response | β Performs |
| Blood draws | β | β |
| Medication administration | β | β |
6.3 Patient/Family Teaching
6.4 Interdisciplinary Communication (SBAR)
S: Calling to request orders for 68F with UTI and concerning new findings.
B: COPD Γ 6yr. SpOβ 88% RA, new lethargy (change from baseline), blood cultures drawn, UA pending at time of initial call.
A: SpOβ improving concern for urosepsis. No current Oβ order, no antibiotics ordered.
R: Requesting: (1) Oβ order 2L NC target SpOβ 88β92%, (2) empiric antibiotics per protocol, (3) q1h VS order, (4) sepsis protocol if lactate β₯2.0.
7
Implement / Take Action
ADPIE: Implementation CJMM: Step 5 π΄ Abx Gap
7.1 Interventions Executed
| Intervention | Status | Notes |
|---|---|---|
| Fall precautions | β Done | Bed lowest, call light in reach, rails up |
| Oβ supplemental | β³ Pending HCP | Not yet applied at time of initial documentation |
| Continuous SpOβ monitoring | β In progress | Per unit protocol |
| IV access | β οΈ Unknown | Not documented |
| Blood cultures | β Drawn | Pending results |
| CBC / BMP / Lactate | β Drawn | Lactate <2.0 confirmed; others pending |
| Reorientation | β In progress | Patient lethargic initially; now more alert |
| Antibiotics | π΄ CRITICAL GAP | E. coli confirmed β escalate immediately; IV Ceftriaxone 1g recommended |
| Analgesic | β³ Pending order | Not yet administered |
| Medication reconciliation | β Not complete | Critical outstanding task |
7.2 Monitoring Parameters
| Parameter | Escalation Threshold | Action |
|---|---|---|
| SpOβ | <88% despite Oβ | Increase Oβ, notify HCP immediately |
| MAP | <65 mmHg | Notify HCP; fluid challenge per order |
| RR | >22 breaths/min | Notify HCP; reassess respiratory status |
| Lactate | β₯2.0 mmol/L | Activate sepsis protocol per HCP |
| Mental status | Worsening β harder to arouse | Notify HCP immediately; SBAR |
7.3 Real-Time Adaptations
None documented at time of implementation.
8
Evaluate Outcomes
ADPIE: Evaluation CJMM: Step 6 ~1h post-intervention
8.1 Actual vs. Expected Outcomes
| # | Diagnosis | Target | Current Status | Met? |
|---|---|---|---|---|
| 1 | Risk for Sepsis | Lactate <2.0, hemodynamics stable; abx within 1h of UA | Lactate <2.0 confirmed; HR/BP stable; antibiotic NOT initiated despite confirmed E. coli | β οΈ Partial |
| 2 | Impaired Urinary Elimination | Antibiotic within 1h of UA result; decreased dysuria within 24h | E. coli >100k confirmed; antibiotic not yet ordered | π΄ Not Met |
| 3 | Impaired Gas Exchange | SpOβ β₯88% on Oβ (COPD target) | SpOβ 92% on 2L NC β COPD target achieved | β Met |
| 4 | Acute Confusion | Oriented to name/place/time by 4h | More alert and responsive β improving | β Progressing |
| 5 | Acute Pain | Pain β€3/10 after analgesic | Pain unchanged β analgesic not yet administered | β Not Met |
8.2 Trending Data Since Intervention
| Cue | At Assessment | Now | Trend |
|---|---|---|---|
| SpOβ | 88% on RA | 92% on 2L NC | β COPD target achieved |
| Mental status | Lethargic; drowsy but arousable | More alert and responsive | β Improving |
| Lactate | Pending | <2.0 | β Septic shock pathway less likely |
| HR | 68 | No new data | β Stable; monitor |
| BP | 138/82 | No new data | β Stable |
| Dysuria / urinary sx | Frequency, urgency, suprapubic pain | Unchanged | β Antibiotics not initiated |
| UA | Pending | +nitrites, +leukocyte esterase, E. coli >100k CFU | π΄ Treatment required now |
| CBC / BMP / Blood cultures | Pending | Still pending | β οΈ Awaiting |
8.3 Contributing Factors
UA Resulted β E. coli >100,000 CFU/mL β Critical update
- Confirms E. coli (gram-negative rod) β most common urosepsis pathogen
- +nitrites (gram-neg bacteriuria) + +leukocyte esterase (WBC in urine)
- Antibiotic initiation is NOW indicated β 1-hour bundle clock resets from this result
- HCP escalation required immediately with UA result in hand
- Culture/sensitivity pending (24β48h) β empiric IV ceftriaxone appropriate; de-escalate per sensitivity
Lactate <2.0 β Maintained significance
- Sepsis-3: lactate β₯2.0 required for sepsis classification; <2.0 reduces septic shock risk
- Does NOT rule out infection β E. coli is confirmed; antibiotics are no longer optional
- Serial lactate recommended β gram-negative bacteremia risk; lactate can rise if treatment delayed
SpOβ 92% on 2L NC β Target achieved (COPD-adjusted)
- BTS/GOLD: 88β92% is appropriate for COPD; do NOT escalate to 94β98%
- Do NOT increase Oβ delivery without HCP order β hypercapnic drive risk
AMS improving β Significant correlation
- AMS improvement after Oβ suggests lethargy was primarily hypoxia-driven
- Acute Confusion may be secondary to Impaired Gas Exchange β continue monitoring for full reorientation
8.4 Intervention Modifications
| Diagnosis | Decision | Rationale |
|---|---|---|
| Risk for Sepsis | π΄ Re-escalate | E. coli confirmed; antibiotic is overdue; gram-negative bacteriuria without treatment = active urosepsis risk |
| Impaired Urinary Elimination | π΄ Escalate immediately | E. coli >100k confirmed; every hour of delay increases sepsis risk |
| Impaired Gas Exchange | β Continue | SpOβ 92% on 2L NC; target 88β92% maintained; do not over-oxygenate |
| Acute Confusion | β Continue | Patient more alert; escalate reorientation; monitor for full return to baseline |
| Acute Pain | β οΈ Escalate | Pain unchanged; patient alert enough to rate; include analgesic in HCP call |
SBAR Update β Call with UA Result
S: Calling to report critical UA result for 68F with UTI/urosepsis risk on 4 West.
B: COPD Γ 6yr. SpOβ now 92% on 2L NC. Lactate <2.0. AMS improving. Blood cultures and CBC/BMP pending.
A: UA resulted: +nitrites, +leukocyte esterase, E. coli >100,000 CFU/mL. No antibiotic has been ordered or started. Active urosepsis risk with confirmed gram-negative bacteriuria.
R: Requesting: (1) IV Ceftriaxone 1g IV q24h, (2) analgesic order (acetaminophen), (3) confirm culture/sensitivity will guide de-escalation. Will you be updating orders now?
8.5 New Cues / Loop Indicator
| Trigger | Re-Enter Phase |
|---|---|
| β UA resulted β E. coli >100k | β Re-entered Phase 3 (complete) |
| Culture/sensitivity (24β48h) | Phase 3 β de-escalate or adjust antibiotic |
| CBC / BMP / blood cultures result | Phase 3 β organ dysfunction, bacteremia |
| Antibiotic initiated | Phase 7 + Phase 8 (re-evaluate 4β6h post) |
| AMS resolves or worsens | Phase 4 β Prioritize Hypotheses |
| Serial lactate β if rising despite treatment | Phase 4 β escalate sepsis hypothesis |
8.6 Evaluation Documentation
At ~1h post-intervention: SpOβ 92% on 2L NC β COPD target met. AMS improving β likely hypoxia-driven. Lactate <2.0 β reassuring against septic shock. UA resulted: E. coli >100,000 CFU/mL confirmed. Antibiotic initiation is overdue and is the highest clinical priority. Pain management outstanding. CBC, BMP, blood cultures pending. Escalate to HCP immediately.
π΄ Outstanding Actions Requiring Follow-Up
- URGENT: Contact HCP NOW with UA result β E. coli >100k CFU confirmed; request IV Ceftriaxone 1g q24h + analgesic order.
- Antibiotic initiation immediately upon order receipt.
- Analgesic (acetaminophen) order β include in same HCP call.
- Medication reconciliation β full med list (meds still unknown; affects antibiotic safety and drug interactions).
- Re-evaluate all outcomes 4β6 hours after antibiotic initiation.
- Serial lactate β repeat if symptoms persist or worsen despite antibiotic initiation.
- Re-enter Phase 3 when culture/sensitivity returns (24β48h) β guide antibiotic de-escalation.
- Re-enter Phase 3 when CBC, BMP, blood cultures result β may reveal organ dysfunction or bacteremia.
- Formal orientation assessment (patient now more alert).
- Patient/family teaching when patient fully alert.
Document generated using the CJMM/ADPIE Combined 8-Phase Clinical Judgment Model